AVPR2 and nephrogenic diabetes insipidus: On the other hand, by fusing ADAR2 (an adenosine deaminase that catalyzes RNA A-to-I editing) to catalytically inactive Cas13b, Cox et al. were able to program RNA editing to correct disease-relevant mutations, such as G878A (AVPR2 arginine vasopressin receptor 2) in X-linked nephrogenic diabetes insipidus and G1517A (FANCC Fanconi anemia complementation group C) in Fanconi anemia [183].